

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

EFM-19

RRID:CVCL_0253

Type: Cell Line

Proper Citation

RRID:CVCL_0253

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0253

Proper Citation: RRID:CVCL_0253

Description: Cell line EFM-19 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:6589426](#), [PMID:10969801](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EFM-19

Synonyms: EFM19

Cross References: BTO:BTO_0006447, CLO:CLO_0002888, EFO:EFO_0002175, MCCL:MCC:0000144, CLDB:cl1141, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:683, BioSample:SAMN03471840, BioSample:SAMN10988267, cancercellines:CVCL_0253, Cell_Model_Passport:SIDM01056, ChEMBL-Cells:ChEMBL3308502, ChEMBL-

Targets:CHEMBL1075439, Cosmic:906851, Cosmic:1603196, Cosmic:2165019, Cosmic-CLP:906851, DepMap:ACH-000330, DSMZ:ACC-231, DSMZCellDive:ACC-231, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906851, GEO:GSM344364, GEO:GSM344414, GEO:GSM350527, GEO:GSM783976, GEO:GSM843497, GEO:GSM847250, GEO:GSM847460, GEO:GSM886999, GEO:GSM888068, GEO:GSM1172949, GEO:GSM1669754, IARC_TP53:21321, IGRhCellID:EFM19, LiGeA:CCLE_105, LINCS_HMS:51113, LINCS_LDP:LCL-1311, PharmacDB:EFM19_321_2019, PRIDE:PXD030304, Progenetix:CVCL_0253, PubChem_Cell_line:CVCL_0253, SLKBase:3411, Wikidata:Q54832051

ID: CVCL_0253

Record Creation Time: 20220427T215830+0000

Record Last Update: 20260829T232606+0000

Ratings and Alerts

No rating or validation information has been found for EFM-19.

No alerts have been found for EFM-19.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sobsey CA, et al. (2024) mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors. Cancer research communications, 4(8), 2058.

Albrecht J, et al. (2024) Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. Molecular oncology.

Andlovic B, et al. (2023) IFN γ primes cancer cells for Fusicoccin-induced cell death via 14-3-3 PPI stabilization. Cell chemical biology, 30(6), 573.

Brix N, et al. (2021) Analysis of clonogenic growth in vitro. Nature protocols, 16(11), 4963.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. Cell, 181(7), 1596.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.

Guan J, et al. (2019) Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. *Cell*, 178(4), 949.